Abstract Library

#3030 Targeting CXCR4 and Thioredoxin Reductase in Theranostics of Atypical Carcinoid and Neuroendocrine Carcinoma

Introduction: Atypical carcinoid and small cell lung cancer (SCLC) are currently incurable. There is thus a critical need for new diagnostic and therapeutic strategies for lung neuroendocrine neoplasms (LNEN). Chemokine receptor 4 (CXCR4), a G protein coupled receptor and theranostic target, plays a crucial role in metastases of LNEN. We hypothesize combination of thioredoxin reductase (TR) inhibitor represents a metabolic strategy to enhance cytotoxicity in peptide-receptor radionuclide therapy (PRRT) of LNEN.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Liu D

Authors: Liu D, Fath M, Robles Planells C, Balk E, Bellizzi A,

Keywords: CXCR4, thioredoxin reductase inhibitor, theranostics, atypical carcinoid, small cell lung cancer,

#1640 SDHB Mutation in a Young Patient with a Metastatic Paraganglioma of the Urinary Bladder

Introduction: Paragangliomas are rare tumors that arise from the sympathetic and parasympathetic ganglia that can possess an inherited trait.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Lambrescu I, Cima L, Leca B, Martin S, Fica S,

Keywords: paragangliomas, SDHB mutation,

#194 Pancreatic Neuroendocrine Tumors: Experience of Endocrinology Department of the University Hospital of Coimbra

Introduction: Pancreatic neuroendocrine tumors (PNETs) are uncommon neoplasms, comprising 1-2% of all pancreatic tumors. The majority are nonfunctional. Of the functional tumors, insulinomas are the most common.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Vieira A, Santos J, Gomes L, Moreira A, Alves M,

Keywords: pancreatic neuroendocrine tumors, insulinoma, hereditary tumor syndromes,